马拉维重性抑郁障碍成人整合式慢性照护的有效性、成本效果与正向外部性(IC3D):一项阶梯楔形整群随机对照试验
在马拉维内科和二级医院共14家卫生机构开展阶梯楔形整群随机对照试验,纳入506例新诊断重性抑郁障碍成人并 enrolled 487例,采用团体问题管理Plus与抗抑郁药的阶梯式照护模式。结果显示干预与抑郁症状减少2.60分、功能改善1.69分及抑郁 odds 降低相关,作者认为整合照护有效并可借助现有基础设施扩展服务。
要点
- IC3D整合照护与抑郁症状减少2.60分(95%CI -3.35至-1.86)相关。
- 功能改善1.69分(95%CI -2.73至-0.65),抑郁 odds 比为0.62(95%CI 0.51至0.74)。
- 作者认为整合照护有效并可借助现有基础设施扩展服务。
核心结论
- 对重性抑郁障碍合并慢性健康问题者,整合照护可有效减轻抑郁症状、改善功能并降低抑郁 odds,且可借助现有基础设施扩展服务。
研究设计与样本
- 在马拉维内科区14家卫生机构开展阶梯楔形整群随机对照试验,机构按卫生中心或二级医院分层后随机分配至五个试验序列,干预启动按3个月周期交错。
- 纳入年龄≥18岁、新诊断重性抑郁障碍且正在整合慢性照护门诊积极入组者,排除高自杀风险或精神病性症状者。
- 采用团体问题管理Plus与抗抑郁药的阶梯式照护模式,由咨询员和临床官员在整合慢性照护门诊提供,每3个月评估一次,持续27个月。
- 主要结局为27个月内抑郁症状严重程度(PHQ-9)、当前抑郁发作(PHQ-9评分>10)和功能(WHO残疾评估量表2.0)的变化,采用意向性治疗视角的纵向混合效应回归分析。
- 2021年9月1日至2022年4月28日共筛查15562人次,识别506例(3%)重性抑郁障碍成人,入组487例(3%),其中女性395例(81%)、男性92例(19%)。
主要发现
- 分配至IC3D与抑郁症状减少2.60分(95%CI -3.35至-1.86;d -0.61)相关。
- 分配至IC3D与功能改善1.69分(95%CI -2.73至-0.65;-0.27)相关。
- 治疗推广后抑郁 odds 降低(调整 OR 0.62,95%CI 0.51至0.74)。
关键数值与推荐
- 当前抑郁发作定义为PHQ-9评分>10。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In low-income and middle-income countries, individuals with major depressive disorder often do not receive screening and treatment. We assessed effectiveness and cost-effectiveness of an integrated care model for treating major depressive disorder in Malawi, accounting for two sets of positive externalities: household benefits and improvements in comorbidities. METHODS: In this stepped-wedge, cluster-randomised, controlled trial, 14 health facilities in Neno District, Malawi, introduced screening, diagnosis, and treatment for people with major depressive disorder, using a stepped-care model of group Problem Management Plus and antidepressant therapy. Adults (ie, aged ≥18 years) residing in facility catchment areas, newly diagnosed with major depressive disorder, and actively enrolled in an integrated chronic care clinic were eligible for inclusion. People identified with high suicidal risk or psychotic symptoms were excluded. Health facilities were categorised into two strata (ie, health centres or secondary hospitals) and randomly allocated to one of five trial sequences, with intervention initiation staggered across sequences in 3-month periods. Participants were masked to trial sequence, data collectors were masked to treatment assignment, and the chief statistician was masked to treatment assignment until analysis. Services were delivered by counsellors and clinical officers at integrated chronic care clinics, and assessments took place at 3-month intervals over 27 months. Primary outcomes were changes in depressive symptom severity (measured with the Patient Health Questionnaire-9 [PHQ-9]), current depressive episode (PHQ-9 score of >10), and functioning (measured with the WHO Disability Assessment Schedule 2.0) over the 27-month period. Longitudinal mixed-effects regression analyses assessed outcomes from an intention-to-treat perspective. The trial was registered with ClinicalTrials.gov (NCT04777006) and is completed. FINDINGS: Between Sept 1, 2021, and April 28, 2022, we conducted 15 562 screenings, resulting in 506 (3%) adults identified with major depressive disorder and 487 (3%) enrolled (395 [81%] women and 92 [19%] men). Assignment to IC3D corresponded to a 2·60-point (95% CI -3·35 to -1·86; d -0·61) reduction in depressive symptoms and 1·69-point (-2·73 to -0·65; -0·27) improvement in functioning, reflecting a reduced odds of depression after treatment roll-out (adjusted odds ratio 0·62, 95% CI 0·51 to 0·74). INTERPRETATION: Integrated care for people with major depressive disorder and chronic health conditions is effective at reducing depressive symptoms, improving functioning, and reducing the odds of depression, and facilitates expansion of services through existing infrastructure. FUNDING: National Institute of Mental Health.
引用
- McBain RK, Mwale O, Mpinga K, et al. Effectiveness, cost-effectiveness, and positive externalities of integrated chronic care for adults with major depressive disorder in Malawi (IC3D): a stepped-wedge, cluster-randomised, controlled trial. Lancet. 2024. PMID: 39488229. doi:10.1016/S0140-6736(24)01809-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。